phrykt

Pulse Biosciences, Inc. (PLSE): who owns it and who trades it

As of Nov 16, 2026, PLSE insiders reported 7 open-market sales worth $2.9M and 6 purchases worth $13.5M in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kevin Patrick Danahy (Chief Commercial Officer), with $2.9M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Pulse Biosciences

From the latest filings

Overall: more buying than selling. Funds, insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PLSE

107 funds and institutions reported PLSE shares worth $321M at the end of Q2 2026, about 17% of the company. The largest holder is BlackRock, Inc. with 2.1%.

Funds and institutions (13F) 17%Everyone else 83%

10 largest owners, by share of the company

BlackRock, Inc.2.1%
Bank of America Corp2.1%
Vanguard Capital Management LLC1.2%
Portolan Capital Management, LLC1.1%
T. Rowe Price Associates1.1%
Balyasny Asset Management L.P.1.1%
Citadel Advisors LLC0.9%
California State Teachers Retirement System0.8%
Geode Capital Management, LLC0.8%
State Street Corp0.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.1.47M2.15%$40.7M+9%
Bank of America Corp1.45M2.12%$40.1M+67%
Vanguard Capital Management LLC788,6401.16%$21.9M-3%
Portolan Capital Management, LLC753,3331.10%$20.9M+3%
T. Rowe Price Associates748,6381.10%$20.8M+4938%
Balyasny Asset Management L.P.718,1031.05%$19.9M+171%
Citadel Advisors LLC626,5140.92%$17.4M+341%
California State Teachers Retirement System567,8830.83%$20.5M+2600%
Geode Capital Management, LLC536,2760.79%$14.9M+9%
State Street Corp529,6240.78%$14.7M+16%
Massachusetts Financial Services Co462,7340.68%$12.8MNo change
UBS Group AG275,6690.40%$7.6M+712%
Griffin Asset Management, Inc.227,2850.33%$6.3M+1%
Vanguard Portfolio Management LLC179,4970.26%$5M+9%
Northern Trust Corp173,5900.25%$4.8M-7%
Charles Schwab Investment Management Inc151,9910.22%$4.2M+3%
Sixth Street Partners Management Company, L.P.151,9910.22%$4.2MNew
Vanguard Fiduciary Trust Co131,2530.19%$3.6M+0%
Point72 Asset Management, L.P.106,4570.16%$3MNew
Norges Bank105,6470.15%$2.9MNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, PLSE insiders reported $13.5M of open-market purchases and $2.9M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$13.5M
6 trades, 3 people
Sales, 12 months
$2.9M
7 trades, 1 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Sep 1, 2026
Filed Sep 2, 2026

Purchases and sales by month

$13.3M$13.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 1, 2026Liane Rae TeplitskyChief Operating OfficerPurchase1,001$49.95$50KForm 4
Aug 31, 2026Liane Rae TeplitskyChief Operating OfficerPurchase1,024$48.80$50KForm 4
Aug 28, 2026Liane Rae TeplitskyChief Operating OfficerPurchase1,034$48.35$50KForm 4
Aug 26, 2026Liane Rae TeplitskyChief Operating OfficerPurchase1,036$48.24$50KForm 4
May 11, 2026Robert W DugganDirectorPurchase660,233$19.69$13MForm 4
May 11, 2026Paul A LavioletteCEOPurchase15,000$19.69$295KForm 4
Feb 18, 2026Kevin Patrick DanahyChief Commercial OfficerSale plan5,000$23.64$118KForm 4
Feb 17, 2026Kevin Patrick DanahyChief Commercial OfficerSale plan20,000$23.63$473KForm 4
Feb 13, 2026Kevin Patrick DanahyChief Commercial OfficerSale plan20,000$23.53$471KForm 4
Feb 12, 2026Kevin Patrick DanahyChief Commercial OfficerSale plan20,000$23.37$467KForm 4
Feb 11, 2026Kevin Patrick DanahyChief Commercial OfficerSale plan20,000$25.20$504KForm 4
Feb 10, 2026Kevin Patrick DanahyChief Commercial OfficerSale plan20,000$23.52$470KForm 4
Feb 9, 2026Kevin Patrick DanahyChief Commercial OfficerSale plan20,000$21.45$429KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Robert W DugganDirector, 10% owner$13M–May 11, 2026
Kevin Patrick DanahyChief Commercial Officer–$2.9MFeb 18, 2026
Paul A LavioletteChief Executive Officer, Director$295K–May 11, 2026
Liane Rae TeplitskyChief Operating Officer$200K–Sep 1, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PLSE short interest

Low short interest. 4.1% of PLSE shares are sold short: about 1 share in 25. Over the last 12 reports the number of shares short went down 10%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.90M PLSE shares were sold short, 4.1% of the shares outstanding, down 3.5% from the report before. At the average daily volume of 351,715 shares, buying them all back would take about 8.2 trading days (days to cover).

Shares short, % of all shares

4.07%May 15Oct 304.84%

Days to cover

8.2May 15Oct 3012.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.90M4.07%-3%351,7158.2
Oct 15, 20263.00M4.21%-9%417,4377.2
Sep 30, 20263.31M4.64%+6%590,5335.6
Sep 15, 20263.14M4.40%+1%806,1283.9
Aug 31, 20263.12M4.38%+13%392,8467.9
Aug 14, 20262.77M3.88%-7%433,3906.4
Jul 31, 20262.98M4.18%+3%426,1877.0
Jul 15, 20262.89M4.24%+1%248,70311.6
Jun 30, 20262.86M4.19%+1%433,5956.6
Jun 15, 20262.82M4.13%-9%325,9178.7
May 29, 20263.09M4.52%-4%294,87710.5
May 15, 20263.22M4.72%+10%463,5846.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Pulse Biosciences company events

Pulse Biosciences filed 32 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 6, 2026.

  1. Nov 6, 2026AnnouncementPulse Biosciences, Inc. announced interim six-month results from its PRECISE-BTN clinical study. Filing
  2. Nov 5, 2026ResultsReleased financial results. Filing
  3. Oct 14, 2026AnnouncementPulse Biosciences, Inc. announced entering into certain agreements with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida, and its affiliates, which together form a commercial and clinical partnership between them to explore the clinical utility of the Company's… Filing
  4. Oct 7, 2026AnnouncementPulse Biosciences, Inc. announced that it had achieved its enrollment target of 164 evaluable patients in its NANOPULSE-AF clinical study evaluating the Company’s nPulse™ Cardiac Catheter System for the treatment of atrial fibrillation. Filing
  5. Sep 15, 2026AgreementPulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC as sales agent, pursuant to which the Company may offer and sell, from time to time, through Mizuho, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering… Filing
  6. Sep 15, 2026AnnouncementPulse Biosciences, Inc. announced completion of patient enrollment in its PRECISE-BTN clinical study evaluating the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules. Filing
  7. Aug 6, 2026AgreementPulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC as sales agent, pursuant to which the Company may offer and sell, from time to time, through Mizuho shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering… Filing
  8. Aug 6, 2026ResultsReleased financial results. Filing
  9. Jul 29, 2026AnnouncementPulse Biosciences, Inc. announced surpassing the enrollment midpoint of its NANOPULSE-AF clinical study, a prospective, multicenter, pivotal, clinical investigation currently evaluating the Company’s nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal… Filing
  10. Jun 12, 2026VoteReported shareholder vote results. Filing
  11. Jun 10, 2026AnnouncementPulse Biosciences, Inc. issued a press release announcing that it will deliver an irrevocable election to redeem the outstanding common stock warrants issued on July 3, 2024 in connection with the Company’s rights offering pursuant to its Registration Statement on Form S-3, as amended (File No.… Filing
  12. May 6, 2026AnnouncementThe Board of Directors of Pulse Biosciences, Inc. approved resolutions permitting TD Securities (USA) LLC, as sales agent, to sell Company common stock to one or more Company affiliates pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between TD Cowen and the… Filing
  13. May 4, 2026AnnouncementPulse Biosciences, Inc. announced accelerated enrollment timelines in its NANOPULSE-AF clinical trial. Filing
  14. Apr 27, 2026AnnouncementShared information with investors. Filing
  15. Apr 16, 2026AnnouncementShared information with investors. Filing
  16. Apr 9, 2026LeadershipChief Operating Officer Appointment Pulse Biosciences, Inc. has appointed Liane R. Teplitsky as its Chief Operating Officer, effective as of April 8, 2026. Filing
  17. Apr 7, 2026AnnouncementPulse Biosciences, Inc. issued a press release announcing the first enrollment of patients in its NANOPULSE-AF clinical study, a prospective, multicenter, pivotal, clinical investigation currently evaluating the Company’s nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant… Filing
  18. Mar 27, 2026LeadershipThe Compensation Committee of the Board of Directors of Pulse Biosciences, Inc. awarded the Company’s Chief Technology Officer, Darrin R. Uecker, for his continued leadership of the Company’s product development efforts for the treatment of atrial fibrillation, a grant of restricted stock units… Filing
  19. Mar 17, 2026AnnouncementPulse Biosciences, Inc. issued a press release announcing an organizational realignment to support the Company’s increasing focus on developing its nsPFA electrophysiology catheters and other cardiac devices for the treatment of atrial fibrillation. Filing
  20. Mar 12, 2026AnnouncementPulse Biosciences, Inc. issued a press release announcing the first enrollment of patients in the investigator-sponsored clinical study of its proprietary Vybrance™ Percutaneous Electrode System as a potential treatment for papillary thyroid microcarcinoma, a small, slow-growing, and most common… Filing
  21. Mar 9, 2026AnnouncementPulse Biosciences, Inc. issued a press release announcing long-term follow-up data from its nPulse™ Vybrance™ Percutaneous Electrode System first-in-human feasibility study. Filing
  22. Mar 3, 2026AnnouncementShared information with investors. Filing
  23. Mar 2, 2026LeadershipAmended an earlier report. Kevin P. Danahy, the Chief Commercial Officer of Pulse Biosciences, Inc. gave notice that he was resigning from the Company, effective immediately. Filing
  24. Feb 27, 2026LeadershipKevin P. Danahy, the Chief Commercial Officer of Pulse Biosciences, Inc. gave notice that he was resigning from the Company, effective immediately. Filing
  25. Feb 19, 2026ResultsReleased financial results. Filing
  26. Feb 19, 2026AgreementPulse Biosciences, Inc. entered into an equity distribution agreement with TD Securities (USA) LLC as sales agent, pursuant to which the Company may offer and sell, from time to time, through TD Cowen shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering… Filing
  27. Feb 6, 2026AnnouncementPulse Biosciences, Inc. issued a press release announcing 6- and 12-month data from its nPulse TM Cardiac Catheter first-in-human feasibility study. Filing
  28. Jan 14, 2026AnnouncementShared information with investors. Filing
  29. Jan 9, 2026LeadershipThe Board of Directors of Pulse Biosciences, Inc. elected Maria Sainz to the Board, effective immediately. Filing
  30. Dec 18, 2025AnnouncementPulse Biosciences, Inc. issued a press release announcing the approval of its Investigational Device Exemption (IDE) submission by the U.S. Food and Drug Administration, allowing the Company to proceed with the initiation of its NANOPULSE-AF clinical study for the treatment of paroxysmal atrial… Filing
  31. Dec 12, 2025VoteReported shareholder vote results. Filing
  32. Dec 9, 2025AnnouncementPulse Biosciences, Inc. issued a press release announcing a research collaboration with The University of Texas MD Anderson Cancer Center to examine the use of the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for treatment of thyroid cancers. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Pulse Biosciences financials

Famous investors that hold PLSE

3 of the 50 well-known investors we track reported holding PLSE in their latest 13F filing. The largest position is Ken Griffin's, worth $74.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.48M$74.1M0.0%+137%
Steve Cohen · Point72 Asset ManagementQ3 2026188,727$9.4M0.0%+77%
Israel Englander · Millennium ManagementQ3 2026141,509$7.1M0.0%+502%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Pulse Biosciences, Inc. (PLSE) stock

Who owns the most PLSE stock?

The largest reported owner of Pulse Biosciences, Inc. (PLSE) is BlackRock, Inc., with 2.1% of the company. In total, 107 funds and institutions reported holding PLSE at the end of Q2 2026, together about 17% of the shares. See the largest owners.

Are PLSE insiders buying or selling?

In the last 12 months, PLSE insiders reported 6 open-market purchases worth $13.5M and 7 sales worth $2.9M. The latest trade was on Sep 1, 2026. See every trade.

What is the short interest in PLSE?

As of Oct 30, 2026, 2.90M PLSE shares were sold short, 4.1% of the shares outstanding, down 3.5% from the report before. At the average daily volume of 351,715 shares, buying them all back would take about 8.2 trading days (days to cover). See the history.

Which famous investors hold PLSE?

3 of the 50 well-known investors we track reported PLSE in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $74.1M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.